HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Nephrology

 

The Endocrinology Network® nephrology clinical resource center is our hub for the latest in news and developments related to nephrology and renal impairment from the perspective of an endocrinologist. Be sure to check back often for the latest in nephrology and CKD.

Risk of Kidney Decline in T1D Heightened for People of African Caribbean Ethnicity

September 03, 2022

An analysis of data from more than 5500 people with type 1 diabetes and preserved kidney function at baseline suggests patients of African Caribbean ethnicity had a more than 50% greater risk of kidney function decline of 50% or greater than patients of other ethnic backgrounds.

Finerenone Reduces All-Cause Mortality, Sudden Cardiac Death in Type 2 Diabetes

August 29, 2022

An analysis of the FIDELITY program from ESC Congress 2022 details an 11% reduction in risk of all-cause mortality and a 25% reduction in risk of sudden cardiac death among patients with type 2 diabetes and chronic kidney disease.

Real-World Data Links Rosuvastatin to Nephrotoxicity

July 22, 2022

An analysis of real-world EHR data from more than 900,000 statin users suggests use of rosuvastatin was associated with an 8% greater risk of hematuria, a 17% greater risk of proteinuria, and a 15% higher risk of developing kidney failure requiring replacement therapy such as dialysis or transplantation compared to atorvastatin use.

Empagliflozin Use Could Reduce Risk of Kidney Stones in T2D

June 16, 2022

An analysis of 20 randomized clinical trials comparing empagliflozin against placebo therapy in patients with type 2 diabetes suggests use of the SGLT2 inhibitor could reduce risk of developing kidney stones by nearly 40%.

Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022

June 06, 2022

After new data from the Diabetes Prevention Program Outcomes Study suggested neither metformin nor lifestyle intervention addressed the cardiovascular risk in patients with prediabetes, we asked experts at ADA 2022 if it was time to rethink metformin as first-line therapy in type 2 diabetes.

Tirzepatide and Kidney Outcomes, with Hiddo Heerspink, PharmD, PhD

June 05, 2022

Hiddo Heerspink, PharmD, PhD, discusses a SURPASS-4 analysis examining kidney outcomes among patients receiving tirzepatide vs insulin glargine and provides perspective on the next steps for research as well as education.